LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads) on and off LinkedIn. Learn more in our Cookie Policy.
Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings.
RPh, CPh, PhD — Oncology Infusion Pharmacy Services Manager at Moffitt Cancer Center — Do not judge each day by the harvest you reap, but by the seeds that you plant.
Pembrolizumab, marketed as Keytruda, is a groundbreaking medication in the field of oncology, primarily used in the treatment of various types of cancer. Its mechanism of action revolves around the modulation of the immune system, immunotherapy, specifically targeting the interaction between cancer cells and T cells, which are crucial components of the immune systems response against malignancies. At the molecular level, pembrolizumab functions as a monoclonal antibody targeting the program death 1PD1 receptor, A protein on the surface of T cells. PD1 is an immune checkpoint that plays a key role in preventing the immune system from attacking the body's own tissues. However, many cancer cells exploit this checkpoint to avoid being attacked by the immune system. They express programmed death ligand one, which binds to the PD1 receptor on T cells, affectively sending an inhibitory signal that reduces the T cells ability to initiate an immune response against these cancer cells. Pembrolizumab works by binding to the PD1 receptor, blocking its interaction with its ligand. This blockade inhibits the PD1 mediated signaling pathway, preventing the OFF signal from being sent to the T cells. As a result, the T cells remain active and capable of attacking and destroying cancer cells. By releasing the immune systems breaks in this way, pembrolizumab allows for a more robust and effective immune response against cancer. This mechanism of action has proven effective in treating various types of cancers. Pembrolizumab is primarily indicated for the treatment of advanced Melanoma, a type of skin cancer and non small cell lung cancer. Additionally, it's approved for use in treating head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and urothelial carcinoma. Its effectiveness across a range of cancers is attributed to its fundamental mechanism of enhancing the immune systems ability to recognize and fight cancer cells. Pembrolizumab is part of a broader class of drugs known as immune checkpoint inhibitors, which have revolutionized cancer treatment in recent years. Similar drugs that target the PD1 PDL 1 pathway include nivolumab, Opdivo, and atezolizumab. Tecentriq. Nivolumab, developed by Bristol-Myers Squibb, is another PD1 inhibitor with a mechanism of action similar to pembrolizumab. It binds to the PD1 receptor on T cells, preventing PDL one from sending inhibitory signals. AT is Eliza MAP, developed by Genentech, a member of the Roche Group, targets the other side of the same pathway by binding to PDL one on tumor cells and immune cells, preventing it from interacting with PD1 receptors. These drugs have emerged in a new era in cancer treatment, offering hope to patients with various types of advanced cancers. Their ability to enhance the immune systems natural capacity to fight cancer represents a significant shift from traditional cancer treatments, focusing instead on harnessing the body's own defenses. The success of pembrolizumab and its counterparts in improving outcomes for cancer patients underscores the potential of immunotherapy as a cornerstone of cancer treatment. Mark's Keytruda has demonstrated a robust financial performance over the last few years. In 2019, the sales for Keytruda were $11.1 billion. This figure saw a substantial increase in 2020, with sales reaching $14.4 billion. The growth trajectory continued in 2021, with Keytruda generating $17.2 billion in sales. The upward trend persisted into 2022, with sales amounting to nearly $21 billion. This consistent increase in sales underscores Keytruda significant role in cancer treatment and its market dominance. Adding to this, the patent for Keytruda is expected to expire in 2028, which will be a pivotal moment for Merck in terms of market competition and strategy.
RPh, CPh, PhD — Oncology Infusion Pharmacy Services Manager at Moffitt Cancer Center — Do not judge each day by the harvest you reap, but by the seeds that you plant.
𝐂𝐨𝐮𝐥𝐝 𝐅𝐑𝐔𝐙𝐀𝐐𝐋𝐀™ 𝐫𝐞𝐝𝐞𝐟𝐢𝐧𝐞 𝐦𝐂𝐑𝐂 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭?
Takeda's new release, #FRUZAQLA, marks a pivotal shift in metastatic colorectal cancer care. As the first oral therapy targeting all three VEGF receptor kinases, it promises a novel approach for patients who have exhausted other options.
The edge?
FRUZAQLA™ demonstrated significant gains in both overall and progression-free survival against placebos in Phase 3 trials. This is a new direction for patient care.
Why pivot to FRUZAQLA™ now?
It offers a chemotherapy-free alternative, crucial for enhancing quality of life in mCRC treatments. This positions FRUZAQLA™ not just as a medication, but as a cornerstone in modern oncology strategies.
How will FRUZAQLA™ fit into your current treatment landscape?
Share your thoughts!
𝐏.𝐒. 𝐃𝐨𝐧'𝐭 𝐟𝐨𝐫𝐠𝐞𝐭 𝐭𝐨 𝐫𝐞𝐩𝐨𝐬𝐭 ♻️ 𝐭𝐡𝐢𝐬 𝐟𝐨𝐫 𝐨𝐭𝐡𝐞𝐫𝐬.
#Cancer#Oncology#Oncolyst#ColorectalCancer
𝐍𝐨𝐭𝐞: This is for education purpose. Please consult your doctor before opting for any treatment.
Physician Engagement Manager | Founder of USMLE Research Hub | Dow Medical College Graduate | Researcher & Educator | Empowering Students in Research | Open to New Connections
📢 New Publication Alert! 🚨
We're excited to share our latest systematic review exploring novel regimens and treatment strategies in neoadjuvant therapy (NACT) for colorectal cancer (CRC)!
In this comprehensive analysis, we dove deep into the latest advancements in NACT, covering: 🔹 Cytotoxic drugs 🔹 Targeted therapies 🔹 Immunotherapy approaches
Our findings highlight the potential benefits and challenges of these novel therapies and the critical need for further research to optimize NACT use and improve outcomes for CRC patients. The evolution of neoadjuvant strategies is reshaping treatment paradigms, opening doors to more precise, personalized care.
Check out the article for insights into the future of CRC treatment and the exciting prospects for precision medicine and immunotherapy in clinical practice!
Link: https://lnkd.in/dxG6qXsT#ColorectalCancer#NeoadjuvantTherapy#CancerResearch#Oncology#PrecisionMedicine#Immunotherapy#ClinicalTrials#SystematicReview
🚨FDA Approves Obecabtagene Autoleucel for Relapsed/Refractory B-ALL
FDA Approves Obecabtagene Autoleucel for Relapsed/Refractory B-ALL
On November 8, 2024, the FDA approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.) for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). This second-generation CD19-directed CAR T-cell therapy demonstrated promising efficacy in clinical trials, with 42% of patients achieving complete remission within three months.
Learn more about its mechanism and clinical implications: https://lnkd.in/dkbpiVdvMark GeyerAmerican Association for Cancer Research#Cancer#Leukemia#ALL#MedEd#MedNews#Health#Medicine#OncoDaily#Oncology
𝗠𝘆𝗿𝗶𝗮𝗱 𝗚𝗲𝗻𝗲𝘁𝗶𝗰𝘀 𝗶𝘀 𝗲𝘅𝗰𝗶𝘁𝗲𝗱 𝘁𝗼 𝗯𝗲 𝗽𝗮𝗿𝘁 𝗼𝗳 𝘁𝗵𝗲 𝗘𝗦𝗠𝗢 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗳𝗿𝗼𝗺 𝘁𝗼𝗱𝗮𝘆, 𝗠𝗮𝘆 𝟭𝟱, 𝘁𝗼 𝗙𝗿𝗶𝗱𝗮𝘆, 𝗠𝗮𝘆 𝟭𝟳, 𝗶𝗻 𝗕𝗲𝗿𝗹𝗶𝗻!
𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 𝗼𝗻 𝗘𝗻𝗱𝗼𝗣𝗿𝗲𝗱𝗶𝗰𝘁®
Gain certainty in breast cancer treatment with our accurate predictive and prognostic test, endorsed with LoE1A in ESMO Guidelines.
𝗘𝗻𝗱𝗼𝗣𝗿𝗲𝗱𝗶𝗰𝘁® 𝗽𝗿𝗼𝘃𝗶𝗱𝗲𝘀 𝗰𝗿𝘂𝗰𝗶𝗮𝗹 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗼𝗿 𝗘𝗥+ 𝗛𝗘𝗥𝟮- 𝗲𝗮𝗿𝗹𝘆-𝘀𝘁𝗮𝗴𝗲 𝗯𝗿𝗲𝗮𝘀𝘁 𝗰𝗮𝗻𝗰𝗲𝗿
- Assess the risk of distant recurrence within 10 years.
- Evaluate the personalized benefit of chemotherapy at 10 years.
- Determine late recurrence risk up to 15 years.
A clear cutoff empowers you to make confident, evidence-based decisions on adjuvant chemotherapy and endocrine therapy.
𝗖𝗼𝗻𝗻𝗲𝗰𝘁 𝘄𝗶𝘁𝗵 𝘂𝘀 𝗮𝘁 𝗕𝗼𝗼𝘁𝗵 𝟮𝟵 𝘁𝗼𝗱𝗮𝘆:
Visit us to learn more about EndoPredict® - our team is eager to discuss how we can collaborate to integrate this solution into your practice. Stay tuned for updates and insights during the congress!
#ESMOBreast24#MyriadGenetics#EndoPredict#BreastCancerCare#OncologyInnovation
Great News in Cancer Treatment! 🧬💊
The NHS has become the first in Europe to offer Quizartinib, a new life-extending treatment for patients with acute myeloid leukaemia (AML) and the FLT3-ITD mutation. This innovative drug, fast-tracked by the NHS Cancer Drugs Fund, significantly boosts survival rates when combined with chemotherapy, offering hope for long-term remission.
Patients on Quizartinib had a median survival of 31.9 months—double that of those on placebo (15.1 months). It’s a major step forward for cancer care and a positive outcome for patients and their families.
#CancerCare#NHS#AML#Oncology#Innovation#LifeExtendingTreatment
